AGC Biologics, a global biopharmaceutical CDMO, will partner with Novavax, Inc., a biotech company developing next-gen vaccines, for the large-scale GMP production of Matrix-M, the adjuvant component of Novavax’ coronavirus vaccine candidate, NVX-CoV2373. Matrix-M is designed to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology. AGC Biologics will optimize process development fo...